Summit Therapeutics Inc.
As of Oct 22, 2026, Summit Therapeutics is in Stage 1, the basing phase, now in week 7 (since Sep 10, 2026). It closed at $15.55, 41.1% below its 52-week high and below its 200-day average, which is falling.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SMMT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SMMT among Biotechnology238th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …238 | SMMT | Stage 1 · wk 7 | 41 | −5.5% |
Summit Therapeutics: quick answers
What stage is Summit Therapeutics in?
As of Oct 22, 2026, Summit Therapeutics (SMMT) is in Stage 1, the basing phase. It entered Stage 1 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Summit Therapeutics in an uptrend?
Not yet. Summit Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 4.3% below its 200-day average, which is falling.
How far is Summit Therapeutics from its 52-week high?
Summit Therapeutics closed at $15.55 on Oct 22, 2026, 41.1% below its 52-week high of $26.38. Its 52-week low is $12.43.
How has Summit Therapeutics performed over the past year?
As of Oct 22, 2026, Summit Therapeutics is down 17.0% over the past year and down 11.2% so far in 2026.
Which sector and industry is Summit Therapeutics in?
Summit Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.